Emergent BioSolutions Inc. 8K

Emergent BioSolutions reported lower Q1 2026 revenues but positive net income and higher profitability guidance for 2026, supported by new partnerships, significant government MCM contracts, and a recent debt refinancing.

Emergent BioSolutions Inc. reported unaudited first quarter 2026 results, with total revenues of $156.1 million, down 30% year-over-year, and net income of $6.8 million (4% margin), alongside adjusted EBITDA of $35.6 million (23% margin). The revenue decline was driven primarily by lower sales of anthrax and smallpox medical countermeasures due to timing of U.S. and international government procurements, partially offset by sharply higher sales of BAT and other products. Management highlighted two new strategic manufacturing partnerships (with SAB Biotherapeutics for a type 1 diabetes candidate and with Substipharm Biologics for a Japanese Encephalitis vaccine), a completed term loan refinancing with a new $150 million facility and amended asset-backed loan facility to improve liquidity and reduce interest expense, and various commercial and government-contract wins, including over $200 million in new MCM-related awards from U.S. and Canadian government partners. The company reaffirmed its 2026 total revenue and net loss guidance but raised its 2026 adjusted net income and adjusted EBITDA outlook, reflecting stronger expected underlying profitability, and it also noted a newly authorized share repurchase program of up to $50 million running through March 31, 2027.

Filing Facts

CIK

1367644

Ticker

-

Form

8K

Source Type

sec

Accession

0001367644-26-000059

Alert Tier

6